S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, Forecast & News

$148.12
-1.94 (-1.29 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$147.87
Now: $148.12
$150.50
50-Day Range
$122.95
MA: $137.73
$151.59
52-Week Range
$113.52
Now: $148.12
$153.03
Volume397,882 shs
Average Volume557,445 shs
Market Capitalization$8.38 billion
P/E Ratio12.10
Dividend YieldN/A
Beta1.15
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone011-353-1634-7800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.89 billion
Cash Flow$16.61 per share
Book Value$45.71 per share

Profitability

Net Income$447.10 million

Miscellaneous

Employees1,360
Market Cap$8.38 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.


Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its quarterly earnings data on Tuesday, November, 5th. The specialty pharmaceutical company reported $4.10 EPS for the quarter, topping the Zacks' consensus estimate of $3.19 by $0.91. The specialty pharmaceutical company earned $537.70 million during the quarter, compared to the consensus estimate of $523.92 million. Jazz Pharmaceuticals had a return on equity of 27.99% and a net margin of 29.61%. The firm's revenue was up 14.6% on a year-over-year basis. During the same period in the prior year, the business earned $3.58 EPS. View Jazz Pharmaceuticals' Earnings History.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Jazz Pharmaceuticals.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share guidance of $15.50-16.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $14.96. The company issued revenue guidance of $2.1-2.18 billion, compared to the consensus revenue estimate of $2.11 billion.

What price target have analysts set for JAZZ?

14 Wall Street analysts have issued 12-month price objectives for Jazz Pharmaceuticals' stock. Their forecasts range from $135.00 to $208.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $171.08 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price. View Analyst Price Targets for Jazz Pharmaceuticals.

What is the consensus analysts' recommendation for Jazz Pharmaceuticals?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jazz Pharmaceuticals.

What are Wall Street analysts saying about Jazz Pharmaceuticals stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Jazz’s key drug, Xyrem, continues to witness improved volume trends in 2019 on the back of awareness efforts. The label expansion of Xyrem in pediatric patients has improved the top line further. Management expects Xyrem's volume growth to continue in the second half. Sunosi's launch in July 2019 complements the sleep franchise and its successful commercialization may offset a decline in Xyrem’s sales following patent expiry in 2023. Jazz’s leukemia drug, Vyxeos, has also witnessed strong growth so far in 2019. Its launch in Europe boosted sales in 2019. However, Jazz has been facing supply crunch for its leukemia drug, Erwinaze, owing to constrained manufacturing capacity, which is likely to continue in second half. Defitelio sales also vary every quarter." (9/13/2019)
  • 2. HC Wainwright analysts commented, "Our $147 12-month target (from $153) is based on a DCF, which reflects a strong 15% 2019-22 cash- flow CAGR, a 10% WACC discount rate, and negative 3.5% terminal growth after 2022 given conservatively assumed modest Xyrem franchise headwinds partially offset by other products’ continued growth." (8/8/2019)
  • 3. Mizuho analysts commented, "We raise our PT to $147 from $137 based on two recent positive catalysts: approval of Sunosi (solriamfetol for excessive sleepiness), and last night’s positive data in the Phase III trial of JZP-258 (low sodium Xyrem). Both these events were largely expected and we reiterate our Neutral rating on JAZZ." (3/27/2019)
  • 4. Cantor Fitzgerald analysts commented, "We have an Overweight rating and a 12-month price target of $185 on JAZZ shares. We believe that the sleep franchise durability remains underappreciated and that the company has an interesting hemo/oncology business that could drive the next leg of growth and evolution for JAZZ. We believe that data readouts in 2019 and upward earnings revisions in both segments of the business will drive upside to JAZZ’s current share price. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $185 price target." (3/26/2019)

Has Jazz Pharmaceuticals been receiving favorable news coverage?

Press coverage about JAZZ stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Jazz Pharmaceuticals earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Jazz Pharmaceuticals.

Are investors shorting Jazz Pharmaceuticals?

Jazz Pharmaceuticals saw a increase in short interest in November. As of November 29th, there was short interest totalling 3,080,000 shares, an increase of 5.1% from the November 14th total of 2,930,000 shares. Based on an average daily trading volume, of 554,600 shares, the short-interest ratio is presently 5.6 days. Currently, 5.6% of the company's shares are short sold. View Jazz Pharmaceuticals' Current Options Chain.

Who are some of Jazz Pharmaceuticals' key competitors?

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), NVIDIA (NVDA), Celgene (CELG), Baidu (BIDU), Biogen (BIIB) and Alphabet (GOOG).

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the folowing people:
  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Matthew P. Young, Exec. VP & CFO (Age 50)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 56)
  • Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 56)
  • Mr. Paul Treacy, Sr. VP of Technical Operations (Age 58)

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (2.55%), Boston Partners (2.41%), Congress Asset Management Co. MA (0.95%), Wedge Capital Management L L P NC (0.49%), Parametric Portfolio Associates LLC (0.42%) and Point72 Asset Management L.P. (0.38%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Karen J Wilson, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul Treacy, Rick E Winningham, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.

Which institutional investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Assenagon Asset Management S.A., Virginia Retirement Systems ET AL, Man Group plc, Rhenman & Partners Asset Management AB, Squarepoint Ops LLC, Boston Advisors LLC and State Street Corp. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Catherine A Sohn, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patricia Carr, Paul Treacy and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.

Which institutional investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., PGGM Investments, Zurcher Kantonalbank Zurich Cantonalbank, GW&K Investment Management LLC, State of New Jersey Common Pension Fund D, Hancock Whitney Corp, California Public Employees Retirement System and First Trust Advisors LP. View Insider Buying and Selling for Jazz Pharmaceuticals.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $148.12.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $8.38 billion and generates $1.89 billion in revenue each year. The specialty pharmaceutical company earns $447.10 million in net income (profit) each year or $12.24 on an earnings per share basis. Jazz Pharmaceuticals employs 1,360 workers across the globe.View Additional Information About Jazz Pharmaceuticals.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is http://www.jazzpharma.com/.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected]


MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  923 (Vote Outperform)
Underperform Votes:  402 (Vote Underperform)
Total Votes:  1,325
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel